Clinical trial • Phase I • Neurology
MTX46943 for Alzheimer's disease
Phase I trial of MTX46943 for Alzheimer's disease. 123 participants.
Overview
- Trial Therapeutic Area
- Neurology
- Trial Disease
- Alzheimer's disease
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 14-07-2025
- First CTIS Authorization Date
- 04-09-2025
Trial design
Phase I trial across 1 site in Netherlands.
- Single Multiple Or Escalation Dose Combined
- Yes
- Target Sample Size
- 123
Eligibility
Recruits 123 Vulnerable population selected; no further details on the type of vulnerable population, or on consent/assent handling, are provided in the CTIS record..
- Vulnerable Population
- Vulnerable population selected; no further details on the type of vulnerable population, or on consent/assent handling, are provided in the CTIS record.
Recruitment
- Planned Sample Size
- 123
- Recruitment Window Months
- 10
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 123
Netherlands
- Earliest CTIS Part Ii Submission Date
- 04-09-2025
- Latest Decision Or Authorization Date
- 26-02-2026
- Processing Time Days
- 175
- Number Of Sites
- 1
- Number Of Participants
- 123
Sites
- Site Name
- Pharmaceutical Research Associates Group B.V.
- Department Name
- Program Management
- Contact Person Name
- Maria Velinova
- Contact Person Email
- maria.velinova@iconplc.com
Sponsor
Primary sponsor
- Full Name
- Muna Therapeutics ApS
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Denmark
Contract research organisations
- Name
- Pharmaceutical Research Associates Group B.V.
- Responsibilities
- Listed in trialSites as site/program management contact (department: Program Management); contact person Maria Velinova (email: maria.velinova@iconplc.com).
Investigational products
- Investigational Product Name
- MTX46943
Related trials
Other published trials that may interest you.